Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)

August 16, 2021

Edgewise announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy, which confers the benefits that Fast Track designation provides. They are continuing to make good progress with their Phase 1 trial and will be enrolling a cohort of adults with Becker soon.

Please see the attached press release issued today for more information. For additional questions, contact [email protected].

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open